Kim D. Blickenstaff net worth and biography

Kim Blickenstaff Biography and Net Worth

Director of Nuvation Bio

Mr. Blickenstaff is the Executive Chairman and Director of Tandem Diabetes Care, Inc., and previously served as the company’s President and Chief Executive Officer. Prior to that, he served as Chairman and Chief Executive Officer of Biosite Incorporated, a provider of medical diagnostic products, from 1988 until its acquisition by Inverness Medical Innovations, Inc. in 2007. Mr. Blickenstaff previously served as a Director of Medivation, Inc., until its acquisition by Pfizer in 2016, and a Director of DexCom, Inc., a provider of continuous glucose monitoring systems. Mr. Blickenstaff was formerly a certified public accountant and has more than 20 years of experience overseeing the preparation of financial statements. He held various positions in finance, operations, research management, sales management, strategic planning and marketing with Baxter Travenol, National Health Laboratories and Hybritech Incorporated. He received a B.A. in political science from Loyola University Chicago and an M.B.A. from the Graduate School of Business, Loyola University Chicago.

What is Kim D. Blickenstaff's net worth?: The estimated net worth of Kim D. Blickenstaff is at least $466,504.10 as of November 20th, 2024. Mr. Blickenstaff owns 195,190 shares of Nuvation Bio stock worth more than $466,504 as of May 5th. This net worth evaluation does not reflect any other investments that Mr. Blickenstaff may own. Learn More about Kim D. Blickenstaff's net worth.
How do I contact Kim D. Blickenstaff?: The corporate mailing address for Mr. Blickenstaff and other Nuvation Bio executives is 1500 BROADWAY SUITE 1401, NEW YORK NY, 10036. Nuvation Bio can also be reached via phone at 332-208-6102 and via email at ir@nuvationbio.com. Learn More on Kim D. Blickenstaff's contact information.
Has Kim D. Blickenstaff been buying or selling shares of Nuvation Bio?: Kim D. Blickenstaff has not been actively trading shares of Nuvation Bio within the last three months. Most recently, on Tuesday, June 11th, Kim D. Blickenstaff bought 172,189 shares of Nuvation Bio stock. The stock was acquired at an average cost of $2.90 per share, with a total value of $499,348.10. Following the completion of the transaction, the director now directly owns 172,189 shares of the company's stock, valued at $499,348.10. Learn More on Kim D. Blickenstaff's trading history.
Who are Nuvation Bio's active insiders?: Nuvation Bio's insider roster includes Kim Blickenstaff (Director), Xiangmin Cui (Director), Jennifer Fox (CFO & Sec. ), David Hung (Founder), David Hung (CEO), Robert Mashal (Director), and Oleg Nodelman (Director). Learn More on Nuvation Bio's active insiders.
Are insiders buying or selling shares of Nuvation Bio?: During the last year, Nuvation Bio insiders bought shares 6 times. They purchased a total of 1,196,778 shares worth more than $2,803,500.47. The most recent insider tranaction occured on April, 7th when CEO David Hung bought 300,000 shares worth more than $486,000.00. Insiders at Nuvation Bio own 29.9% of the company. Learn More about insider trades at Nuvation Bio.
Information on this page was last updated on 4/7/2025.

Kim D. Blickenstaff Insider Trading History at Nuvation Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/11/2024	Buy	172,189	$2.90	$499,348.10	172,189

Kim D. Blickenstaff Buying and Selling Activity at Nuvation Bio

Nuvation Bio Company Overview

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Today's Range

Now: $2.39

$2.38

$2.52

50 Day Range

MA: $1.96

$1.65

$2.46

2 Week Range

Now: $2.39

$1.54

$3.97

Volume

2,682,119 shs

Average Volume

2,143,597 shs

Market Capitalization

$809.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42